Comparison of DNA Damage in Granulosa Cells of Women Undergoing Controlled Ovarian Stimulation in in Vitro Fertilization Protocols with the Recombinant Human Follicle-stimulating Hormones Corneumon, Gonal-F, Pergoveris and Puregon: a Randomized Trial

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2024 Mar 5

PMID 38441601

Authors

Ximena Alcala-Sanchez

Pedro Cuapio-Padilla

Carlos Salazar-Lopez

Ricardo Rodriguez

Mario Teteltitla

Ivan Bahena

Miguel Betancourt

Eduardo Casas

Fahiel Casillas

Alma Lopez

Edmundo Bonilla

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the DNA damage in granulosa cells (GCs) of women undergoing ovarian-stimulated cycles with four widely used recombinant human follicle-stimulating hormones (rhFSH) in in vitro fertilization (IVF) protocols (Corneumon, Gonal-F, Pergoveris and Puregon).

Methods: A randomized trial was carried out at a Mexican hospital. GCs were isolated from 18 women with infertility undergoing assisted reproductive techniques (ART). Four controlled ovarian stimulation (COS) protocols including Corneumon, Gonal-F, Pergoveris or Puregon were used. GCs DNA damage was assessed by the Comet assay. Two parameters were measured: comet tail length (CTL), and Olive tail moment (OTM, the percentage of DNA in the tail multiplied by the distance between the center of the tail and head).

Results: Use of the different hrFSH in COS caused variable and statistically significant levels of DNA damage in GCs of infertile women. CTL was similar in the Corneumon and Pergoveris groups (mean values of 48.73 and 55.18, respectively) and Corneumon CTL was significantly lower compared to the Gonal-F and Puregon groups (mean values of 61.98 and 91.17, respectively). Mean OTM values were significantly lower in Corneumon and Pergoveris groups, compared to Gonal-F and Puregon groups (25.59, 27.35, 34.76, and 47.27, respectively).

Conclusion: Use of Corneumon and Pergoveris in COS caused statistically significantly lower levels of DNA damage in GCs of infertile women undergoing ART, which could potentially correlate with better reproductive outcomes.

References

Spoletini R, Di Trani M, Renzi A, Fedele F, Scaravelli G . Psychological care for infertile couples undergoing assisted reproductive technology: a national study on the characteristics of counselling services. Ann Ist Super Sanita. 2022; 58(1):46-54. DOI: 10.4415/ANN_22_01_07. View

Di M, Wang X, Wu J, Yang H . Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2022; 307(6):1713-1726. DOI: 10.1007/s00404-022-06565-6. View

Namavar Jahromi MD B, Parsanezhad MD M, Shomali MD Z, Bakhshai MD P, Alborzi MD M, Moin Vaziri MD PhD N . Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. Iran J Med Sci. 2018; 43(3):248-260. PMC: 5993897. View

Ge H, Tollner T, Hu Z, Da M, Li X, Guan H . Impaired mitochondrial function in murine oocytes is associated with controlled ovarian hyperstimulation and in vitro maturation. Reprod Fertil Dev. 2012; 24(7):945-52. DOI: 10.1071/RD11212. View

Ding J, Tan X, Song K, Ma W, Xiao J, Zhang M . Effect of controlled ovarian hyperstimulation on puberty and estrus in mice offspring. Reproduction. 2017; 154(4):433-444. DOI: 10.1530/REP-16-0572. View

Lavorato H, Oliveira J, Petersen C, Vagnini L, Mauri A, Cavagna M . GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. Eur J Obstet Gynecol Reprod Biol. 2012; 165(1):61-5. DOI: 10.1016/j.ejogrb.2012.07.014. View

Al-Saleh I, Coskun S, Al-Rouqi R, Al-Rajudi T, Eltabache C, Abduljabbar M . Oxidative stress and DNA damage status in couples undergoing fertilization treatment. Reprod Fertil. 2022; 2(2):117-139. PMC: 8812407. DOI: 10.1530/RAF-20-0062. View

Baratas A, Gosalvez J, de la Casa M, Camacho S, Dorado-Silva M, Johnston S . Cumulus Cell DNA Damage as an Index of Human Oocyte Competence. Reprod Sci. 2021; 29(11):3194-3200. PMC: 9646542. DOI: 10.1007/s43032-021-00817-7. View

Perez-Ruiz I, Meijide S, Ferrando M, Larreategui Z, Ruiz-Larrea M, Ruiz-Sanz J . Ovarian stimulated cycles reduce protection of follicular fluid against free radicals. Free Radic Biol Med. 2019; 145:330-335. DOI: 10.1016/j.freeradbiomed.2019.10.004. View

10.

Williams R, Vensel T, Sistrom C, Kipersztok S, Rhoton-Vlasak A, Drury K . Pregnancy rates in varying age groups after in vitro fertilization: a comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim). Am J Obstet Gynecol. 2003; 189(2):342-6. DOI: 10.1067/s0002-9378(03)00728-2. View

11.

Moon S, Choi Y, Ku S, Kim S, Choi Y, Kang I . Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. J Obstet Gynaecol Res. 2007; 33(3):305-15. DOI: 10.1111/j.1447-0756.2007.00529.x. View

12.

Manzi L, Sepe N, Migliaccio W, Lanzoni L, Iozzino L, DAngelo F . Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions. Int J Mol Sci. 2022; 23(12). PMC: 9223809. DOI: 10.3390/ijms23126762. View

13.

Younis A, Clower C, Nelsen D, Butler W, Carvalho A, Hok E . The relationship between pregnancy and oxidative stress markers on patients undergoing ovarian stimulations. J Assist Reprod Genet. 2012; 29(10):1083-9. PMC: 3492583. DOI: 10.1007/s10815-012-9831-x. View

14.

Tice R, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H . Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000; 35(3):206-21. DOI: 10.1002/(sici)1098-2280(2000)35:3<206::aid-em8>3.0.co;2-j. View

15.

Einaudi L, Courbiere B, Tassistro V, Prevot C, Sari-Minodier I, Orsiere T . In vivo exposure to benzo(a)pyrene induces significant DNA damage in mouse oocytes and cumulus cells. Hum Reprod. 2013; 29(3):548-54. DOI: 10.1093/humrep/det439. View

16.

Bosch E, Labarta E, Kolibianakis E, Rosen M, Meldrum D . Regimen of ovarian stimulation affects oocyte and therefore embryo quality. Fertil Steril. 2016; 105(3):560-570. DOI: 10.1016/j.fertnstert.2016.01.022. View

17.

Yates A, Roberts S, Nardo L . Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011; 27(2):629. DOI: 10.1093/humrep/der397. View

18.

Brinsden P, Akagbosu F, Gibbons L, Lancaster S, Gourdon D, Engrand P . A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2000; 73(1):114-6. DOI: 10.1016/s0015-0282(99)00450-1. View

19.

Choo C, Ahn Y, Kim K, Lee J, Moon K, Choi B . Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (Follitrope™) in Inducing Controlled Ovarian Stimulation in Infertile Women in Real-World Practice: a Prospective Cohort Study. Reprod Sci. 2023; 30(9):2842-2852. PMC: 10480279. DOI: 10.1007/s43032-023-01228-6. View

20.

Frydman R, Howles C, Truong F . A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm.... Hum Reprod. 2000; 15(3):520-5. DOI: 10.1093/humrep/15.3.520. View